{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:44:04Z","timestamp":1788407044152,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.rceng.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:07:25Z","timestamp":1717607245000},"page":"428-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral anticoagulant treatment in atrial fibrillation: the AFIRMA real-world study using natural language processing and machine learning"],"prefix":"10.1016","volume":"224","author":[{"given":"J.","family":"Cos\u00edn-Sales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Arias-Cabrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mart\u00ednez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fern\u00e1ndez de Cabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2024.06.002_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int J Stroke"},{"key":"10.1016\/j.rceng.2024.06.002_bib0010","first-page":"259","article-title":"Prevalence of atrial fibrillation in Spain. OFRECE study results","volume":"67","author":"Gomez-Doblas","year":"2014","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.rceng.2024.06.002_bib0015","first-page":"505","article-title":"Prevalence of atrial fibrillation and its associated factors in Spain: an analysis of 6 population-based studies. DARIOS Study","volume":"214","author":"Baena-Diez","year":"2014","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.rceng.2024.06.002_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1474-4422(07)70264-8","article-title":"Atrial fibrillation and stroke prevention","volume":"6","author":"Lip","year":"2007","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.rceng.2024.06.002_bib0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/joim.12468","article-title":"A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation","volume":"279","author":"Lip","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.rceng.2024.06.002_bib0035","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1055\/s-0040-1713889","article-title":"Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?\u2014a systematic review","volume":"120","author":"de Vries","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rceng.2024.06.002_bib0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2024.06.002_bib0045","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2024.06.002_bib0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40256-020-00449-3","article-title":"Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study","volume":"21","author":"Duraes","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.rceng.2024.06.002_bib0055","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.rceng.2024.06.002_bib0060","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ijcard.2015.09.037","article-title":"REal-life evidence of stroke prevention in patients with atrial fibrillation\u2014the RELIEF study","volume":"203","author":"Coleman","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rceng.2024.06.002_bib0065","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis","volume":"116","author":"Lip","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rceng.2024.06.002_bib0070","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"146","author":"Joosten","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2024.06.002_bib0075","doi-asserted-by":"crossref","first-page":"h1885","DOI":"10.1136\/bmj.h1885","article-title":"Development of phenotype algorithms using electronic medical records and incorporating natural language processing","volume":"350","author":"Liao","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.rceng.2024.06.002_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136651","article-title":"Methods to develop an electronic medical record phenotype algorithm to compare the risk of coronary artery disease across 3 chronic disease cohorts","volume":"10","author":"Liao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.rceng.2024.06.002_bib0085","first-page":"404","article-title":"Comparing ICD9-encoded diagnoses and NLP-processed discharge summaries for clinical trials pre-screening: a case study","volume":"2008","author":"Li","year":"2008","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.rceng.2024.06.002_bib0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.arbr.2019.12.023","article-title":"Clinical management of COPD in a real-world setting. a big data analysis","volume":"57","author":"Izquierdo","year":"2021","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.rceng.2024.06.002_bib0095","series-title":"Principles of health interoperability : SNOMED CT, HL7 and FHIR, in health information technology standards","first-page":"1","author":"Benson","year":"2016"},{"key":"10.1016\/j.rceng.2024.06.002_bib0100","first-page":"23","article-title":"Savana: a global information extraction and terminology expansion framework in the medical domain","volume":"57","author":"Espinosa","year":"2016","journal-title":"Procesamiento del Lenguaje Natural"},{"key":"10.1016\/j.rceng.2024.06.002_bib0105","doi-asserted-by":"crossref","DOI":"10.2196\/20492","article-title":"Assessing the performance of clinical natural language processing systems: development of an evaluation methodology","volume":"9","author":"Canales","year":"2021","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.rceng.2024.06.002_bib0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40119-016-0066-2","article-title":"A systematic literature review on the cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation","volume":"5","author":"Pinyol","year":"2016","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.rceng.2024.06.002_bib0120","unstructured":"Informes de posicionamiento terap\u00e9utico UT_ACOD\/V5\/21112016. Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con fibrilaci\u00f3n auricular no valvular A.E.d.M.y.P. Sanitarios, Editor. 2016."},{"key":"10.1016\/j.rceng.2024.06.002_bib0125","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2217\/cer-2019-0079","article-title":"Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study","volume":"8","author":"Ramagopalan","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.rceng.2024.06.002_bib0130","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00415-011-6259-7","article-title":"CHA(2)DS(2)-VASc score and prognosis in ischemic strokes with atrial fibrillation","volume":"259","author":"Giralt-Steinhauer","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.rceng.2024.06.002_bib0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejim.2019.10.026","article-title":"Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation","volume":"71","author":"Bo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rceng.2024.06.002_bib0140","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1185\/03007995.2016.1164676","article-title":"Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain","volume":"32","author":"Lobos-Bejarano","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rceng.2024.06.002_bib0145","first-page":"56","article-title":"Assessment of anticoagulation treatments in non-valvular atrial fibrillation patients diagnosed in a basic health area","volume":"30","author":"Aguilera Alcaraz","year":"2018","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.rceng.2024.06.002_bib0150","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.semerg.2015.08.004","article-title":"[Level of control and treatment adherence of anticoagulation with acenocoumarol in Primary Care]","volume":"42","author":"Precioso Costa","year":"2016","journal-title":"Semergen"},{"key":"10.1016\/j.rceng.2024.06.002_bib0155","first-page":"165","article-title":"ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists","volume":"54","author":"Benezet-Mazuecos","year":"2019","journal-title":"REC: CardioClinics"},{"key":"10.1016\/j.rceng.2024.06.002_bib0160","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-0039-3401823","article-title":"Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"120","author":"Pandey","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rceng.2024.06.002_bib0165","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1055\/s-0040-1713098","article-title":"Navigating NSAID use in patients receiving oral anticoagulation: is there a safe course?","volume":"120","author":"Kent","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rceng.2024.06.002_bib0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","article-title":"Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial","volume":"105","author":"Proietti","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.rceng.2024.06.002_bib0175","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071907","article-title":"Oral anticoagulant switching in patients with atrial fibrillation: a scoping review","volume":"13","author":"Adelakun","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.rceng.2024.06.002_bib0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijcard.2018.05.034","volume":"271","author":"Boriani","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rceng.2024.06.002_bib0185","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2024.06.002_bib0190","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1055\/s-0039-1683428","article-title":"Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study","volume":"119","author":"Hohnloser","year":"2019","journal-title":"Thromb Haemost"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S225488742400081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S225488742400081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T21:11:12Z","timestamp":1722633072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S225488742400081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S225488742400081X"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2024.06.002","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral anticoagulant treatment in atrial fibrillation: the AFIRMA real-world study using natural language processing and machine learning","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2024.05.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}